I guidelines for perioperative evaluation;Diretrizes Brasileiras de dispositivos cardíacos eletrônicos implantáveis (DCEI)

Arquivos Brasileiros de Cardiologia

Volumn 89, Issue 6, 2007, Pages

  Gualandro, Danielle Menosi ^a   Pinho, Claudio ^a   Feitosa, Gilson ^a   Caramelli, Bruno ^a   Martinelli Filho, Martino ^a  

^a Sociedade Brasileira de Arritmias Cardíacas ^*

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CORTICOSTEROID; DOBUTAMINE; ENOXAPARIN; ESMOLOL; GLITAZONE DERIVATIVE; GLYCERYL TRINITRATE; HEPARIN; HYDROCORTISONE; IODINE; IOPANOIC ACID; IOPODATE SODIUM; LEVOTHYROXINE; LIOTHYRONINE; LOW MOLECULAR WEIGHT HEPARIN; MINERALOCORTICOID; PROPRANOLOL; PROPYLTHIOURACIL; SULFONYLUREA DERIVATIVE; THIAMAZOLE; THYROTROPIN; THYROXINE; UNINDEXED DRUG; WARFARIN;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ALGORITHM; ANESTHESIA; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY CATHETERIZATION; ATRIOVENTRICULAR BLOCK; BLOOD CELL COUNT; BLOOD DISEASE; BLOOD PRESSURE MONITORING; BLOOD TRANSFUSION; BODY MASS; BODY TEMPERATURE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CINEANGIOCARDIOGRAPHY; CLINICAL FEATURE; COMA; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CUSHING SYNDROME; DEFIBRILLATOR; DISEASE CLASSIFICATION; ELECTROCARDIOGRAPHY; ENDOCARDITIS; EXERCISE ELECTROCARDIOGRAPHY; GLYCEMIC CONTROL; GYNECOLOGIC SURGERY; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE CONDUCTION; HEMOPHILIA; HIP ARTHROPLASTY; HIP FRACTURE; HOLTER MONITORING; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KNEE ARTHROPLASTY; MEDICAL TECHNOLOGY; METHODOLOGY; MYXEDEMA; NEUROSURGERY; OBESITY; PACEMAKER; PERIOPERATIVE PERIOD; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCINTIGRAPHY; SICKLE CELL ANEMIA; SPINAL CORD INJURY; ST SEGMENT; STRESS ECHOCARDIOGRAPHY; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOPHILIA; THYROID DISEASE; UROLOGIC SURGERY; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE; ARTICLE; BRAZIL; HEART SURGERY; NOMENCLATURE; STANDARD;

BRAZIL; CARDIAC SURGICAL PROCEDURES; HUMANS; PERIOPERATIVE CARE; TERMINOLOGY AS TOPIC;

EID: 41249088565     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2007001800017     Document Type: Review

References (228)

1. Lorga AM, de Paola AAV, Sosa EA, Maia IG, Pimenta J, Gizzi JC, Rassi SG. Diretrizes para implante de marcapasso cardíaco definitivo. Arq Bras Cardiol 1988; 50 (3): 209-212
2. Sosa EA, Paola AAV, Martinelli Filho M, Costa R, Pimenta J, Lorga AM, Maia IG, D'Avila A, Halperein C. Recomendações do Departamento de Arritmias e Eletrofisiologia Clínica (DAEC) da Sociedade Brasileira de Cardiologia para Indicações de Implante de Marcapasso Definitivo, Escolha do Modo de Estimulação e Indicações para Implante de Desfibrilador-Cardioversor Automático. - Arq Bras Cardiol 1995; 64 (6): 579-83.
3. Andrade JCS, Ávila Neto V, Braile DM, Brofman PRS. Costa ARB, Costa R, Galvão Filho SS, Gauch PRA, Lucchese FA, Martinelli Filho M, Medeiros PTJ, Mateos JCP, Pimenta J, Takeda RT. Diretrizes para o Implante de Marcapasso Cardíaco Permanente. Arq Bras Cardiol 2000, 74 (5): 475-80.
4. Lorga AM, Lorga Filho A; D'Ávila A, Rassi Jr A, Paola AAV; Pedrosa A, Costa AB, Peres A, Grupi C, Cirenza, C, Moreira D, Sobral D, Hachul D, D'Andréa, E, Sosa EA, God EMG, Brito FS, Cruz F, Fenelon G, Lima GG, Brito H, Maia IG, Atié J, Jorge JCM, Andrade JC, Mateos, JCP, Ribeiro JC, Pimenta J, Vasconcelos, JT, Gizzi J, Zimerman L, Castilho LAT, Figueiredo M, Martinelli Filho M, Scanavacca MI, Valente N, Medeiros P, Brofman P, Miranda RC, Costa R, Kunyioshi R, Sá R, Rassi, SG, Siqueira S, Galvão S, Nishioka S, Grillo T, Rodrigues TR, Maciel W. Diretrizes para Tratamento de Pacientes com Arritmias Cardíacas. . Arq Bras Cardiol 2002, 79 (5): 1-50.
5. MED-MANUAL, MED-GUIDE 27,201, Coverage Issue Manual §50-1 Cardiac Pacemaker Evaluation services [Effective date: October1,1984].
6. Hayes DL, Friedman PA. Follow-up. In: Hayes DL, Lloyd MA, Friedman PA, editors. Cardiac and Defibrillation: A Clinical Approach. Armonk, NY: Futura 2000: 541-83.
7. Furman S, Parker B, Escher DJ: Transtelephone pacemaker clinic. J Thorac Cardiovasc Surg 1971; 61:827-834.
8. Furman S, Escher DJ: Transtelephone pacemaker monitoring: five years later. Ann Thorac Surg 1975; 20: 326-38.
9. Gillis AM, Phillippon MR, Cassidy MR, Singh M, Dorian P, Love BA, Kerr CR. Guidelines for implantable cardioverter defibrillator follow-up in Canada: A consensus statement of the Canadian Working Group on Cardiac Pacing Br Med J Cardiol 2002; 19(1): 21-28.
10. Mond HG. The Cardiac Pacemaker: Funtion and Malfunction. New York, Grune & Stratton 1983;178.
11. Goldschlager N, Ludmer P, Creamer C. Follow-up of the paced outpacient. In Clinical Cardiac Pacing. Edited by Ka Ellenborgen, GN Kay, BL Wilkoff. Philadelphia, WB Saunders Company 1995: 780-808.
12. Lenive Pa, Sanders R, Markowitz HT. Pacemakaer diagnostics: measured data, event marker, electrogram, and event counter telemetry. In Clinical Cardiac Pacing. Edited by KA Ellenbogen, GN Kay, Company 1995; 639-55.
13. Auricchio A, Hartung W, Geller C, Klein H. Clinical relevance of stored electrograms for implantable cardioverter-defibrillator (ICD) troubleshooting and understanding of mechanisms for ventricular tachyarrhythmias. Am J Cardiol 1996; 78: 33-41.
14. Ferrer MI. Sick Sinus Syndrome. In: Atrial Disease. JAMA 1968; 206: 645.
15. Shaw DB, Holman RR, Gowers JI. Survival. In: Sinoatrial Disorder (Sick Sinus Syndrome). Br Med J 1980; 280: 139.
16. Marneffe M, Gregore M, Waterschoot P, Kestmont P. The sinus node function: normal and pathological. Eur Heart J 1993;14: 649-54.
17. Shaw DB. The etiology of sinoatrial disorder (sick sinus syndrome). Am Heart J 1976; 92: 539.
18. Nieminski KE, Kay RH, Rubin DA. Current concepts andmanagement of the and management sick sinus syndrome. Heart & Lung 1984,13: 675-80.
19. Lee WJ, Wu ML, Lue HC. Sinus node disfunction. In: Children. Acta Paediatrics Sin 1992; 33: 159.
20. Caralis DG, Varghese PJ. Familial sinoatrial node dysfunction: Increased vagal tone A possible aetiology. Br Heart J 1976; 38: 951-2.
21. Shullman VA, Nikulina SI, Puzyrev VP, Saliukov VB, Matiushin GV, Kusaev VV. The etiological aspects of the sick sinus syndrome. Ter Arkh 1993; 5: 38.
22. Andrade ZA, Câmara EJN, Sadigursky M, Andrade SG. Envolvimento do nódulo sinusal na doença de Chagas. Arq Bras Cardiol 1988; 50: 153.
23. Benchimol CB, Kreuzig R, Ginefra P, Schlesinger P, Benchimol AB. A disfunção do nódulo sinusal na cardiopatia chagásica crônica. Arq Bras Cardiol 1977; 30: 337.
24. Shaw DB, Linker NJ, Heaver PA, Evans R. Chronic sinoatrial disorder (sick sinus syndrome): A possible result of cardiac ischaemia. Br Heart J 1987; 58: 598.
25. Fukushima Y, Kanno Y, Itoh T, Watanabe S, Hirokawa M, Miura AB. Sick sinus syndrome in a patient with myeloma-associated amyloidosis. Rinsho Ketsueki 1992; 33: 969.
26. Wang TL, Chen WJ, Liau CS, Lee YT. Sick sinus syndrome as the early manifestation of cardiac hemochromatosis. J Electrocardiol 1994; 27: 91.
27. Szatmary LJ, Solti F, Albared JL, Pisapia A. Intrinsic and extrinsic sinus node dysfunction: diagnostic problems. Cor Vasa 1989; 31: 216.
28. Sauerwein HP, Ruos JC, Becker AE, Dunning AJ. The sick sinus syndrome. Acta Med Scand 1976; 199: 467.
29. Lousada N, Catarino C, Antunes E, et al. Arrhythmic profiles evaluated by Holter's technique in sick sinus syndrome. Rev Port Cardiol 1991; 10: 427.
30. Sutton R, Kenny R. The natural hystory of sick sinus syndrome. PACE 1986; 9: 1110.
31. Simon AB, Janz N. Symptomatic brady-arrhythmias in the adult. Natural history following ventricular pacemaker implantation. PACE 1982; 5: 372.
32. Benditt DG, Benson DW Jr, Kreitt J, et al. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradiarrhythmias. Am J Cardiol 1983; 52: 1223.
33. Sgarbossa EB, Pinski SL, Maloney JD, et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome-relevance of clinical characteristics and pacing modalities. Circulation 1993; 88: 1045.
34. Alboni P, Ratto B, Cappato R, Rossi P, Gatto E, Antonioli GE. Clinical effects of oral teophilline in sick sinus syndrome. Am Heart J 1991; 122: 1361.
35. Saito D, Matsubara K, Yamanari H, et al. Effects of oral teophilline on sick sinus syndrome. J Am Coll Cardiol 1993; 21: 1199.
36. Yang YJ. The natural history of sick sinus syndrome. Chest 1993; 21: 94.
37. Sasaki Y, Shimotori M, Akahane K. Long-term follow-up of patients with sick sinus syndrome: a comparison of clinical aspects among unpaced, ventricular inhibited paced and physiologically paced groups. PACE 1988; 11: 1575.
38. Curzi GF, Mocchegianni R, Ciampani N, Pasetti L, Berrettini U, Purcaro A. Thromboembolism During VVI Permanent Pacing In Cardiac Pacing. In: Gomez FP, (Ed.). Electrophysiology and Tachyarrhythmias. Madrid: Editorial Grouz, 1985: 1203-6.
39. Hluchy J, Milovsky V, Pavlovic M, Uhliarikova H, Makovini M. Parasympathetic overactivity and its evaluation in patients with sinus nodal dysfunction. Int J Cardiol 1991; 33: 357.
40. Mandel WJ, Hayakawa H, Allen HN, Danzig R, Kermaler A. Assessment of sinus node function in patients with the sick sinus syndrome. Circulation 1972; 46: 761-9.
41. Scheibelhofer W, Kaliman J, Laczkovics A, Steinbach K. Rhythm complications in atrial programmed pacing. In: Feruglio G (Ed.). Cardiac Pacing, Electrophysiology And Pacemaker Technology, 1982: 665.
42. Lien WP, Lee YS, Chang FZ, Lee SY, Chen CM, Tsai HC. The sick sinus syndrome. (Natural history of dysfunction of the sino-atrial node). Chest 1977; 72: 628.
43. Rosenqvist M, Brandt J, Schüller H. Atrial versus ventricular pacing in sinus node disease: a treatment comparison study. Am Heart J 1986; 11: 292.
44. Alpert MA, Curtis JJ, Sanfelippo JF, et al. Comparative survival following permanent ventricular and dual-chamber pacing for patients with chronic symptomatic sinus node dysfunction with and without congestive heart failure. Am Heart J 1987; 113: 958.
45. Sugrue DD, Gersh BJ, Holmes DR, Wood DL, Osborn MJ, Hammill SC. Symptomatic "isolated" carotid sinus hypersensitivity: natural history and results of treatment with anticholinergic drugs or pacemaker. J Am Coll Cardiol 1986;7:158-62.
46. Kenny RA, Richardson DA, Steen N, Bexton RS, Shaw FE, Bond J. Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE). J Am Coll Cardiol 2001;38:1491-6.
47. Brignole M, Menozzi C, Gianfranchi L, OddoNE C, Lolli G, Bertulla A. Neurally mediated syncope detected by carotid sinus massage and head-up tilt test in sick sinus syndrome. Am J Cardiol 1991;68:1032-6.
48. The Conduction System Of The Heart. In: Davies MJ, Anderson RH, Becjer AE. London: Butterworth Publishing, 1993.
49. Ruschaupt DG, Khoury L, Thilenius OG, Replogle LR, Arcilla RA. Electrophysiologic abnormalities of children with ostium secundum atrial septal defect. Am J Cardiol 1984; 53: 1643.
50. Akhtar M, Foster JR, Damato AN, Kilne LE, Ruskin JN. Congenitally corrected transposition of the great vessels: localization of the site of ventricular AV block using His-bundle electrograms. Am J Cardiol 1976; 38: 383.
51. Rassi A, Lorga AM, Rassi SG. Abordagem diagnóstica e terapêutica das arritmias na cardiopatia chagásica crônica. In: Germiniani H. Diagnóstico e Terapêutica das Arritmias Cardíacas. Rio de Janeiro: Guanabara Koogan SA, 1990: 225-44.
52. o M, Nishioka SAD, et al. Bloqueio atrioventricular de QRS estreito adquirido: comportamento em seguimento tardio. Arq Bras Cardiol 1995, 65: 27.
53. Langerdorf R, Cvohen H, Gozo EG. Observations on second degree atrioventricular block, including new criteria for the differential diagnosis between type I and type II block. Am J Cardiol 1972; 29: 111.
54. Alpert MA, Curtis JJ, Sanfelippo JF, et al. Comparative survival after permanent after permanent ventricular and dual chamber pacing for patients with chronic high degree atrioventricular block with and without preexistent congestive heart failure. J Am Coll Cardiol 1986; 7: 925-32.
55. Barlow M, Kerr CR, Connollu SJ. Survival quality-of-life, and clinical trials in pacemaker patients. In: Ellenbogen KA, Kay GN, Wilkoff BL, (Eds). Clinical Cardiac Pacing and Defibrillation. 2nd Ed. Philadelphia: WB Saunders, 2000.
56. Bernstein AD, Parsonnet V. Survey of cardiac pacing in the United States In 1989. Am J Cardiol 1992; 69: 331-8.
57. Brady PA, Shen WK, Neubauer AS, et al. Pacing mode and long-term survival in eldery patients with congestive heart failure: 1980-1985. J Interv Cardiovasc Electrophysiol 1997; 1: 193-201.
58. Clarke M, Sutton R, Ward D, et al. Recommendations for pacemaker prescription for symptomatic bradicardia. Br Heart J 1991; 66: 185-91.
59. Connolly SJ, Kerr C, Gent M, et al. Dual-chamber versus ventricular pacing: critical appraisal of current data. Circulation 1996; 94: 578-83.
60. Martinelli M, Nishióka SD, Lopes H, et al. Cardiac pacemakers controlled by autonomic nervous system-driven sensor and related neurohumoral aspects. Progress in biomedical research 2001; 6: 312-7.
61. Martinelli M, Nishióka SD, Lopes H, et al. Neurohumoral behavior in recipients of cardiac pacemaker patients controlled by a closed loop autonomic nervous system-driven sensor. PACE 2000, 23: 1778-82.
62. Josephson, Mark E. Atrioventricular Conduction. In: Josephson, Mark E, editor. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 3rd ed. Malvern: Lippincot Wilkins, 2001. P. 92-109.
63. Wigle ED, Sasson S, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1-83.
64. Maron MS, Olivotto I, Betocchi S et al. Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. N Engl J Med 2003;348:295-303.
65. Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004;350;1320-1327.
66. Chang SM, Lakkis NM, Franklin J, et al. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004;109:824-827.
67. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004;109:452-455.
68. van der Lee C, Cate FJ, Geleijnse ML, et al. Percutaneous Versus Surgical Treatment for Patients With Hypertrophic Obstructive Cardiomyopathy and Enlarged Anterior Mitral Valve Leaflets. Circulation 2005;112:482-488.
69. Yacoub MH. Surgical Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy The Pendulum Swings. Circulation 2005;112:450-452.
70. Woo A, Williams WG, Choi R, et al. Clinical and Echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;11:2033-2041.
71. Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy. Alive and Quite well. Circulation 2005:111:2016-2018.
72. Hassenstein P, Storch HH, Schmitz W. Results of electrical pacing in patients with hypertrophic obstruction cardiomyopathy. Thorax Vask Chir 1975;23:496-498.
73. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive syntomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-2742.(abstract).
74. Gadler F, Linde C, Rydén L. Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term, atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1999;83:553-557.
75. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessement of permaent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927-2933.
76. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J 1997;18:1249-1256.
77. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: A comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol 1999:34:191-196.
78. Pachón-M JCE Pachón-M EI. Síncope - epidemiologia e mecanismos fisiopatológicos. Rev Soc Cardiol Est. São Paulo 1999; 9: 163-74.
79. Abboud FM. Neurocardiogenic syncope. N Engl J Med 1993; 15: 1117.
80. Strasberg B, Sagie A, Erdman S, et al. Carotid sinus hypersensivity and the carotid sinus syndrome. Prog Cardiovasc Dis 1989; 5: 379.
81. Kapoor WN, Peterson J, And Karpf M. Micturition Syncope. JAMA 1985; 253: 796.
82. Kapoor WN, Peterson J, Karpf M. Defecation syncope. A symptom with multiple etiologies. Arch Intern Med 1986; 146: 2377.
83. Waxman MB, Cameron DA, Wald RW. Role of ventricular vagal afferents in the vasovagal reaction. J Am Coll Cardiol 1993; 21: 1138.
84. Mark AL. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. Br Med J 1982; 285: 1599-601.
85. Hachul D, Sosa EA, Consolim F, et al. Reprodutibilidade do teste de inclinação em pacientes com sincope neurocardiogênica. Arq Bras Cardiol 1994; 62: 297-300.
86. Kosinski DJ, Grubb BP, Elliott L, Dubois B. Treatment of malignant neurocardiogenic syncope with dual chamber cardiac pacing and fluoxetine hydrochloride. Pacing Clin Electrophysiol 1995; 18: 1455-7.
87. Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Thomsen PEB, et al. Guidelines on Management (Diagnosis and Treatment) of Syncope. Europace 2004; 6: 467-537.
88. Shannon JR, Diedrich A, Biaggioni I, Tank J, Robertson RM, Robertson D, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med 2002; 112: 355-60.
89. Schroeder C., Bush VE, Noreliffe LJ, Luft FC., Tank J., Jordan J., Hainsworth R. Water drinking acutely improves orthostatic tolerance in healthy subjects. Circ 2002; 106: 2806-11.
90. Mathias C., Young M. Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur J Neurol 2004; 11: 613-9.
91. Jordan JJR, Shannon BK, Black Y, Ali M, Farley F, Costa A, et al. The pressor response to water drinking in humans. A sympathetic reflex? Circ 2000; 101: 504-9.
92. Claydon V., Hainsworth R. Salt Supplementation Improves Orthostatic Cerebral and Peripheral Vascular Control in Patients with Syncope. Hypertension 2004; 43: 809-13.
93. El-Sayed H., Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in the patients with unexplained syncope. Heart 1995; 75: 134-40.
94. Cooper VL, Hainsworth R. Effects of dietary salt on orthostatic tolerance, blood pressure and baroreceptor sensitivity in patients with syncope. Clin Auton Res 2002; 12: 236-41.
95. Krediet CT., Dijk N., Linzer M., Lieshout JJ., Wieling W. Management of vasovagal syncope: controlling or aborting faints by leg croosing and muscle tensing. Circ 2002: 106(13): 1684-9.
96. Brignole M, Croci F, Menozzi C, et al. Isometric arm counterpressure maneuvers to abort impeding vasovagal syncope. J Am Coll Cardiol 2002; 40: 2053-9.
97. Croci F, Brignole M, Menozzi C, Solano A, Donateo P, Oddone P, et al. Efficacy and feasibility of isometric arm counter-pressure manoeuvers to abort impending vasovagal syncope during real life. Europace 2004: 6(4): 287-91.
98. Dijk N, Quartieri F, Blanc J, Garcia-Civera R, Brignole M, Moya A, et al. Effectiveness of Physical Counterpressure Maneuvers in Preventing Vasovagal Syncope. J Am Coll Cardiol 2006; 48:1652-7.
99. Ector H, Reybrouck T, Heidbuchel H, Gewillig M, Van de Werf F. Tilt training: a new treatment for recurrent neurocardiogenic syncope and sever orthostatic intolerance. Pacing Clin Electrophysiol. 1998;21(1 Pt 2):193-6.
100. Abe H, Kondo S, Kohshi K, Nakashima Y. Usefulness of orthostatic self-training for the prevention of neurocardiogenic syncope. Pacing Clin Electrophysiol 2002; 25(10): 1454-8.
101. Di Girolamo E, Di Iorio C, Leonzio L, Sabatini P, Barsotti A. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: a controlled study. Circulation 1999; 100(17): 1798-801.
102. Foglia-Manzillo G, Giada F, Gaggioli G, Bartoletti A, Lolli G, Dinelli M et al. Efficacy of tilt training in the treatment of neurally mediated syncope. A randomized study. Europace 2004; 6(3): 199-204.
103. Mtinangi BL, Hainsworth R. Incresead orthostatic tolerance following moderate exercise training in patients with unexplained syncope. Heart 1998 Dec; 80(6): 596-600.
104. Mtinangi BL, Hainsworth R. Effects of moderate exercise training on plasma volume, baroreceptor sensitivity and orthostatic tolerance in healthy subjects. Exp Physiol 1999 Jan; 84(1): 121-30.
105. Gardhenghi, Rondon, Braga, Scanavacca, Negrão Sosa Hachul. The effects of exercise training on arterial baroreflex sensitivity in neurally mediated syncope patients. Eur Heart J. 2007 Jun 7:
106. Robert Sheldon, Stuart Connolly, Sarah Rose, Thomas Klingenheben, Andrew Krahn. Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope . Circ 2006;113(9):1164-70.
107. Stuart J. Connolly, MD; Robert Sheldon, MD; Kevin E. Thorpe, MMath. Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal Syncope J Amer Med Assoc 2003;289:2224-9.
108. Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, Brignole M. The vasovagal syncope and pacing trial (Synpace). A randomized placebo-controlled study of permanent pacing for treatment of recurrent vasovagal syncope. Eur Heart J 2004;25:1741-1748.
109. Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Moya A, Wieling W, Andresen D, Benditt DG, Vardas P. Early application of an Implantable Loop Recorder allows a mechanism-based effective therapy in patients with recurrent suspected neurally-mediated syncope. Eur Heart J 2006; 27: Eur Heart 1085-1092.
110. Manolio TA, Furberg CD: Epidemiology of sudden cardiac death. In: Akhtar M, Myerburg RJ, Ruskin JN, eds. Sudden Cardiac Death: Prevalence, Sudden Cardiac Death: Mechanisms, and Approaches to Diagnosis and Management. Philadelphia: Williams & Wilkins, 1994: 3-20.
111. Hallstrom AP, Eisenberg MS, Berner L. The persistence of ventricular fibrillation and its implication for evaluating EMS. Emerg Health Serv Q 1983; 1: 41-47.
112. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl N Engl J Med 2002; 346:877-883.
113. Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the multicenter automatic defibrillator implantation trial. J Am Coll Cardiol 2004; 43:1459-1465.
114. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
115. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488.
116. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882-1890.
117. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151-2158.
118. Strickberger SA, Hummel JD BartlettTG, et al. Amiodarone versus implantable cardioverter-defibrillator : randomized trial in patients with with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-1712.
119. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-Resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150
120. Myerburg RJ, Kessler KM, Estes D, et al. Long-term survival after prehospital cardiac arrest: analysis of outcome during an 8 year study. Circulation 1984;70:70:538-46.
121. Furukawa T, Rozanski JJ, Nogami A, Morae K, Gosselin AJ, Lister JW. Time-dependent risk of and predictors for cardiac arrest with chronic coronary artery disease. Circulation 1989;80:599-608.
122. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J. 2001;16:1374-450.
123. The CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (The CASCADE Study). Am J Cardiol 1993;72:280-86.
124. The Antiarrhythmics versus Implantable Dedfibrillator (AVID) Investigators. A comparison of antyarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
125. Domanski MJ, Sanjeev S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 1999;34:1090-5.
126. Connolly SJ, Gent M, Roberts RS et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-32.
127. Sheldon R, Connolly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000;101:1638-40.
128. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone. Circulation 2004;110:112-116.
129. Kuck KH, Cappato R, Siebels J, Ruppel P. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg. Circulation 2000;102:748-54.
130. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21:2071-78.
131. Lau EW, Griffith MJ, Pathmanathan RK, et al. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multicenter prospective randomised clinical trial on the secondary prevention of sudden cardiac death. Europace 2004;6:257-266.
132. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhytmic drugs in survivors of serious ventricular tachyarrhytmias. Results of the Antiarrhytmics versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002;105:2049-57.
133. Klein G, Robin SR, Gent M, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian Implantable Defibrillator Study. Circulation 2001;104:1622-26.
134. Leenhardt A, Lucet V, Denjoy, et al. Catecholaminergic polymorphic ventricular tachycardia. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512-1519
135. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200
136. Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor gene (RyR2) gene in the familial polymorphic ventricular tachycardia.. Circulation 2001; 103: 485-490
137. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378-1384
138. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106: 69-74
139. Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DJ, Jalife J, editors. From Cell to Bedside. 2000: 597-615.
140. Romano C, Gemme G, Pongiglione R. Rare cardiac arrhythmias of the pediatric age. Syncopal attacks due to paroxysmal ventricular fibrillation. Clin Pediatr (Bologna) 1963; 45: 656-683.
141. Ward OC. A new familial cardiac syndrome in children. J Isr Med Assoc 1964; 54: 103-106.
142. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J 1957; 54: 59-68
143. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12: 17-23
144. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803
145. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-811
146. Abbot GW, Sesti F, Splawski I, et, al. MiRP1 forms IKr potassium channels with potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175-187
147. Splawski I, Tristani-Firouzi M, Lehmann MH, et al. Mutations in the hminK gene cause QT syndrome and suppress IKs function. Nat Genet 1997; 17: 338-340
148. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V) 1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 19-31
149. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-639
150. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616-623
151. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-1874
152. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: 1391-1396
153. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify Sodium channel risk for sudden death in patients with ST-segment elevation and and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510-515
154. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293-296
155. Brugada J, Brugada R, Antzelevitch C, et al. Long term follow-up of individuals with the electrocardiographic pattern of right bundle branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105: 73-78.
156. Dumaine R, Towbin JA, Brugada P, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999; 85: 803-809
157. Mok NS, Priori SG, Napolitano C, et al. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol 2003; 14: 407-411
158. Ortega-Carnicer J, Benezet J, Ceres F. Fever-induced ST-segment elevation and T-wave alternans in a patient with Brugada syndrome. Resuscitation 2003; 57: 315-317
159. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110: 1731-173.
160. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: 1853-1860
161. Mizusawa Y, Sakurada H, Nishizaki M,Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada Syndrome: Low-dose Quinidine terapy as an Adjunctive treatament, J Cardiovasc Pharmacol 2006 ; 47 : 359-364
162. Maron BJ, Roberts WC, Epstein SE. Sudden cardiac death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982; 65: 1388-1394.
163. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316: 780-789.
164. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 1987; 316: 844-852.
165. Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J 1994; 72: S10-S12.
166. Wigle ED, Rakowski H, Kimball BP, et al. Circulation 1995; 92: 1680-1692
167. McKenna W. Sudden death in hypertrophic cardiomyopathy: Identification of the "high risk" patient. In Brugada P, Wellens HJJ: Cardiac Arrhythmias: Where to go from here? Mount Kisko, NY, Futura Pub Co, Inc, 1987.
168. Cannan CR, Reeder GS, Bailey KR, et al. Natural history of hypertrophic cardiomyophathy. A population-based study, 1976 through 1990. Circulation 1995; 92: 2488-2495.
169. Kyriakidis M, Triposkiadis F, Anastasakis A, et al. Hypertrophic cardiomyopathy in Greece: clinical course and outcome. Chest 1998; 114: 1091-1096.
170. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology / European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42: 1687-1713.
171. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter- defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412.
172. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332: 1058-1064.
173. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999; 44: 20-36.
174. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I. Circulation 2001; 104: 2113-2116.
175. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyiopathy. A consecutive analysis in 155 patients. Circulation 1989;80: 1259-1268.
176. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86: 730-740.
177. Behr ER, Elliot P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 2002; 6: 482-486.
178. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a review. Pacing Clin Electrophysiol 1995; 18: 1298-1314.
179. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997; 30: 1512-1520.
180. Furlanello F, Bertoldi A, Dallago M, et al. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol 1998; 21: 331-335
181. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia /cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994; 71: 215-218
182. Peters S, Peters H, Thierfelder L. Risk stratification of sudden cardiac death and malignant ventricular arrhythmias in right ventricular dysplasia-cardiomyopathy. Int J Cardiol 1999; 71: 243-250
183. Peters S. Left ventricular impairment in arrhythmogenic right ventricular dysplasia: what we can learn from angiography. Cardiology 1995; 86: 473-476
184. Peters S, Reil GH. Risk factors of cardiac arrest in arrhythmogenic right ventricular dysplasia. Eur Heart J 1995; 16: 77-80
185. Bauce B, Nava A, Rampazzo A, et al. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 2000; 85: 573-579.
186. Marcus F, Towbin JA, Zareba W, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary study: design, and protocol. Circulation 2003; 107: 2975-2978.
187. Jessup M, Brozena S, Review Article - Heart Failure. N Engl J Med 2003;348:2007-18.
188. Bristow MR, Saxon LA, Botteron G, et al., for the COMPANION investigators. Cardiac resynchronization Therapy (CRT) reducces hospitalizations, and CRT + implantable defibrillator (CRT+D), reduces mortality in chronic heart failure: Results of the COMPANION trial. Retrieved August 29, 2003.
189. Bramlet DA, Morris KG, et al. Effect of rate-dependent left bundle branch block on global and regional left ventricular function. Circulation 1983; 67:1059-65.
190. Yu CM, Lin H, Zhang Q, et al. High Prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart 2003; 89:54-60.
191. Bax JJ, Molhoeck SG, et al. Usefulness of myocardial tissue Doppler echocardiography to evaluate left ventricular asynchrony before and after biventricular pacing in patients with idiopadic dilated cardiomyopathy. Am J Cardiol 2003; 91: 94-7.
192. Shamin W, Francis DP, Coats AJS. Intraventricular conduction delay: a predictor of mortality in chronic hart failure? Eur Heart J 1989; 19:47.
193. a.
194. Auricchio A, Stelbrink C, et al. The Pacing Therapies for Congestive Heart Failure (PATH-CHF) study: rationale, design and end-points of a prospective randomized multicenter study. Am J Cardiol 1999; 83:130-5D.
195. Thompson C, Tsiperfal A. Why does the QRS morphology of paced beat chane in patients with biventricular cardiac pacing systems? Prog Cardiovasc Nurs 2002; 17:101-103.
196. Alonso C, leclerq C, Victor F, et al. Electrocardiographic predictive factors of long term clinical improvement with multi-site biventricular pacing in advanced heart failure. Am J Cardiol 1999; 84:1417-21.
197. Cleland JGF, Daubert JC, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352(15): 1539-49.
198. Abraham WT, Fisher WG, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845-53.
199. Linde C, Leclercq C, Rex S, et al. Long term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation In Cardiomyopathies (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8.
200. Gras D, Leclercq C, el al. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. Eur Heart J Failure 2002; 4:311-20.
201. Thackray S, Coletta A, et al. Clinical trial update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur Heart J Failure 2001; 3:491-4.
202. Freemantle N, Tharmanathan P, et al. Cardiac resynchronization for patients with heart failure due to a left ventricular systolic dysfunction - a systematic review and meta-analysis. Eur Heart J Failure 2006; 8:433-40.
203. Leclerq C, walker S, et al. Comparative effects of permanent biventricular and right univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J Failure 2002; 23:1780-7.
204. Leclerq C, Cazeau S, et al. Upgrading from right ventricular pacing to biventricular pacing in previously paced patients with advanced heart failure: a randomized controlled study (The RD-CHF trial) - abstract. European Society of Cardiology Congress. Vienna. Áustria 3 september 2003.
205. Higgins SL, Hummel JD, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42:1454-9.
206. Martinelli M, Costa R, Siqueira SF, Ramires JA. COMBAT - conventional versus multisite pacing for bradyarrhythmia therapy: rationale of a prospective randomized multicenter study. The European Journal of Heart Failure 7 (2005) 219-224.
207. Kindermann M, Hennen B, Jung J, Geisel J, Böhm M, Föhlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol. 2006 May 16;47(10):1946-8.
208. Valls-Bertault V, Fatemi M, Gilard M, Pennec PY, Etienne Y, Blanc JJ. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation. Europace (2004) 6, 438e443
209. Horwich T, Foster E, Marco T, Tseng Z, Saxon L. Effects of Resynchronization Therapy on Cardiac Function in Pacemaker Patients "Upgraded" to Biventricular Devices. J Cardiovasc Electrophysiol, 2004;15:1284-1289.
210. Leon RA, , Greenberg JM, Kanuru N, Baker CM, Mera FV, Andrew L. Smith AL, Langberg JJ, DeLurgio DB, MD. Cardiac Resynchronization in Patients With Congestive Heart Failure and Chronic Atrial Fibrillation Effect of Upgrading to Biventricular Pacing After Chronic Right Ventricular Pacing. J Am Coll Cardiol 2002;39:1258-63
211. North American Society of Pacing and Electrophysiology Lead Extraction Conference Faculty. Recommendations for extraction of chronically implanted transvenous pacing and defibrillator leads: indication, facilities, training. Pacing Clin Electrophysiol 23: 544-551, 2000.
212. Byrd CL Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. Pacing Clin Electrophysiol. 22:1348-57, 1999.
213. Hauser RG, Hayes DL, Kallinen LM, et al. Clinical experience with pacemaker pulse generators and transvenous leads: An 8-year prospective multicenter study. Heart Rhythm 2007; 4(2):154-60. Epub 2006 Oct 12.
214. Wilkoff BL et al. Pacemaker Lead Extraction with the Laser Sheath: Results of the Pacing Lead Extraction With the Excimer Sheath (PLEXES) Trial. J. Am Coll Cardiol. 33: 1671-1676.
215. Kennergren C. Excimer Laser aasisted extraction of permanent pacemaker and ICD leads present experiences of a Europen multi-centre study. Eur J Cardio-thorac Surg 15: 856-860, 1999.
216. Costa R, Martinelli Filho M, Crevelari ES, Stolf NAG, Oliveira AS. Raios Laser na Remoção de Cabo-Eletrodo de Marcapasso e Desfibrilador Implantável. Arq Bras Cardiol 77: 235-8, 2001.
217. Neuzil P, Taborsky M, Rezek Z, , et al. Pacemaker and ICD lead extraction with electrosurgical dissection sheaths and standard transvenous extraction systems: results of a randomized trial. Europace 2007; 9(2):98-104.
218. Erdogan O. Electromagnetic interference on pacemakers. Indian Pacing Electrophysiol J. 2002 Jul 1;2(3):74-8.
219. Occhetta E, Bortnik M, Magnani A, Francalacci G, Marino P. Inappropriate implantable cardioverter-defibrillator discharges unrelated to supraventricular tachyarrhythmias. Europace. 2006 Oct;8(10):863-9. Epub 2006 Aug 17.
220. De Rotte AA, Van Der Kemp P. Electromagnetic interference in pacemakers in single-engine fixed-wing aircraft: a European perspective. Aviat Space Environ Med. 2002 Mar;73(3):179-83. javascript:PopUpMenu2_Set(Menu11908881);
221. Wolber T, Ryf S, Binggeli C, Holzmeister J, Brunckhorst C, Luechinger R, Duru F. Potential interference of small neodymium magnets with cardiac pacemakers and implantable cardioverter-defibrillators. Heart Rhythm. 2007 Jan;4(1):1-4. Epub 2006 Sep 16.
222. Trigano AJ, Azoulay A, Rochdi M, Campillo A. Electromagnetic interference of external pacemakers by walkie-talkies and digital cellular phones: experimental study. Pacing Clin Electrophysiol 1999 Apr;22(4 Pt 1):588-93.
223. Hayes DL, Wang PJ, Reynolds DW, Estes M, Griffith JL, Steffens RA, Carlo GL, Findlay GK, Johnson CM. Interference with cardiac pacemakers by cellular telephones. N Engl J Med 1997;22;336(21):1473-9.
224. Pinski SL, Trohman RG. Interference with cardiac pacing. Cardiol Clin 2000; 18(1):219-39.
225. Epstein MR, Mayer JE, Duncan BW. Use of an ultrasonic scalpel as an alternative to electrocautery in patients with pacemakers. Ann Thorac Surg 1998; 65: 1802-4.
226. Irnich W. Electronic security systems and active implantable medical devices. PACE 2002; 25(8):1235-58.
227. McIvor ME, Redding J, Floden E, Sheppard RC. Study of Pacemaker and Implantable Cardioverter Defibillator Triggering by Electronic Article Surveillance Devices (SPICED TEAS). PACE 1998;21(10):1847-61.
228. Dawson TW, Caputa K, Stuchly MA, Shepard RB, Kavet R, Sastre A. Pacemaker interference by nagnetic fields at power line frequencies. IEEE Trans Biomed Eng 2002;49(3):254-62.